cer-001
Recombinant proteinexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01201837)
Timeline
Indications
Mechanism of action
- Apolipoprotein A-ISupplementation
APOA1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cer-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02697136 | Phase 3 | Dec 1, 2015 | Abionyx, University of Amsterdam |
| NCT02484378 | Phase 2 | Aug 1, 2015 | Abionyx, South Australian Health and Medical Research Institute |
| NCT01515241 | Phase 2 | Jan 1, 2012 | Abionyx, University of Montreal |
| NCT01412034 | Phase 2 | Nov 1, 2011 | Abionyx, University of Amsterdam |
| NCT01201837 | Phase 2 | Mar 1, 2011 | Abionyx, University of Montreal |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abionyx | For profit | 5 | 5 | 2 | 2011 |
| University of Amsterdam | Academic/Hospital | 2 | 0 | 2 | 2011 |
| University of Montreal | Academic/Hospital | 2 | 0 | 1 | 2011 |
| South Australian Health and Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1